Serum C-telopeptide levels predict the incidence of skeletal-related events in cancer patients with secondary bone metastases

Introduction We evaluated serum C-telopeptides (CTX) to see whether they may be useful as predictive markers for disease progression in cancer patients with bone metastases who are being treated with zoledronic acid (ZA). Patients and methods This was a prospective, nonrandomised study in which 26 p...

Full description

Saved in:
Bibliographic Details
Published in:Clinical & translational oncology 2010-08, Vol.12 (8), p.568-573
Main Authors: López-Carrizosa, María Concepción, Samper-Ots, Pilar María, Pérez, Aurora Rodríguez
Format: Article
Language:English
Subjects:
Aged
Aged, 80 and over
Analysis of Variance
Biomarkers, Tumor - blood
Bone and Bones - pathology
Bone Density Conservation Agents - therapeutic use
Bone Neoplasms - metabolism
Bone Neoplasms - pathology
Bone Neoplasms - secondary
Collagen Type I - blood
Diphosphonates - therapeutic use
Disease Progression
Female
Fractures, Spontaneous - pathology
Humans
Imidazoles - therapeutic use
Male
Medicine
Medicine & Public Health
Middle Aged
Neoplasms - pathology
Oncology
Peptides - blood
Prognosis
Prospective Studies
Statistics, Nonparametric
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Introduction We evaluated serum C-telopeptides (CTX) to see whether they may be useful as predictive markers for disease progression in cancer patients with bone metastases who are being treated with zoledronic acid (ZA). Patients and methods This was a prospective, nonrandomised study in which 26 patients with solid tumours and confirmed bone metastases were treated with ZA (4 mg every 3–4 weeks) for 24 months or until a skeletal-related event (SRE) was observed. Serum CTX levels were determined at baseline and 6, 12, 18 and 24 months after study initiation. SRE were evaluated using bone scintigraphy. Results Study participants had prostate (50%), breast (31%), lung (11%) or bladder (8%) tumours. Mean age was 69 (range 52–84) years, and 65% men. At baseline, overall mean CTX levels were 562.47 ± 305.17 pg/dl. Patients who showed disease progression during the study period showed significantly higher CTX levels at baseline and after 18 months of ZA treatment than patients who did not progress ( p = 0.040 and p = 0.006, respectively). Patients with ≥5 bone metastases at diagnosis had significantly higher CTX levels after 18 months of ZA treatment than patients with
ISSN:1699-048X
1699-3055
DOI:10.1007/s12094-010-0555-z